Mount Sinai Receives $6.2 Million Grant from the Steven & Alexandra Cohen Foundation for the Clinical Care of Long Lyme Disease
The Cohen Center for Recovery From Complex Chronic Illnesses will provide care and research for wide range of conditions
Mount Sinai’s Department of Rehabilitation and Human Performance has announced a $6.2 million grant from the Steven & Alexandra Cohen Foundation. The grant will expand the Cohen Center for Recovery From Complex Chronic Illnesses (CoRE) to encompass research and clinical care beyond long COVID to include “long Lyme Disease/Lyme+” as well as other infection-associated complex chronic illnesses.
This funding will be used for new research programs focusing on understanding and highlighting the key similarities and differences between long COVID; long Lyme disease/Lyme+, a collection of infection-associated chronic illnesses related to patients who were initially infected with tick- or vector-borne bacteria; and other infection-associated complex chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome, Ehlers-Danlos syndrome, and other tick-borne diseases. This enhanced understanding will help clinicians and researchers at Mount Sinai develop and test novel therapies for these conditions.
“For decades, people with long Lyme disease have struggled to find centers that can provide knowledgeable and compassionate care for their serious and debilitating symptoms. We are proud that our Center will be one of the few places in the world that is embedded in a major clinical institution to provide this care—this is a patient population that has been without access to adequate care for too long,” says David Putrino, PhD, who will serve as the Nash Family Director of the Cohen Center for Recovery From Complex Chronic Illness. Dr. Putrino is also a Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai and the Director of Rehabilitation Innovation for the Mount Sinai Health System.
“Millions of patients all over the world experience infection-associated complex chronic illnesses, and there are very few clinical centers of excellence that engage in both outstanding clinical care and world-leading research focused on biological discovery,” Dr. Putrino adds. “Since 2020, we have established significant expertise and experience in the clinical management and research of long COVID. Because clinical and biological similarities can exist between long COVID and other infection-associated complex chronic conditions such as long Lyme disease/Lyme+, offering clinical care and research and clinical trial opportunities for people living with long Lyme disease/Lyme+ is a logical and important extension of our Center’s work. This is not about treating all of these conditions in the same way. On the contrary, it is about using this as an opportunity to carefully study how these conditions differ from one another and establish targeted and precise therapies for our patients.”
“Long or chronic Lyme disease and other infection-associated chronic conditions continue to be a growing health crisis,” says Alex Cohen, President of the Steven & Alexandra Cohen Foundation. “We are proud to support compassionate, innovative care for patients who are suffering from complex chronic illnesses.”
At the Center, patients will undergo specialized rehabilitation with a physical therapy team with expertise in autonomic rehabilitation to address autonomic dysfunction, also known as dysautonomia. This condition affects the nerves that regulate involuntary body functions including heart rate, blood pressure, temperature regulation, and hormone release. At least 70 percent of patients with chronic illness experience this as part of their symptoms. Physicians at the Center will medically manage the clinical care of patients and use the latest evidence to prescribe medications that are known to be effective in the management of concurrent conditions such as latent viral reactivation and mast cell activation syndrome (MCAS). MCAS is a condition of immune dysregulation where the body overproduces chemicals that make people experience continual, and often severe, allergic reactions. MCAS is common in infection-associated complex chronic illnesses such as long COVID and long Lyme disease, because a patient’s immune system has become dysregulated as a result of persistent infection or latent virus reactivation.
The Center will offer novel, technological (non-pharmacological) therapies for chronic pain. These evidence-based approaches include virtual, augmented, and mixed reality; transcranial magnetic stimulation and other non-invasive brain stimulation technologies; and audiovisual therapies. Additionally, patients will have access to personalized cognitive rehabilitation for help with cognitive impairment, which is a common symptom of infection-associated complex chronic illnesses. The CoRE will also research novel therapies, including the role of multiple natural supplements in care management, combination therapies of antimicrobials or antivirals to treat persistent infection, hyperbaric oxygen therapy, and photobiomodulation, a form of light therapy.
Accurate advanced testing and diagnosis for Lyme patients is also an important aspect of the Center. Clinicians and staff will move beyond Centers for Disease Control and Prevention-recommended Lyme testing and order comprehensive tick-borne/vector-borne testing from laboratories used by Lyme-literate MDs from accredited labs across New York State.
Dr. Putrino will grow and expand the Center with two co-Directors. Joseph Herrera, DO, Chair of the Department of Rehabilitation and Human Performance for the Mount Sinai Health System, will serve as the Center’s Medical Director, and Amy Proal, PhD, President of the PolyBio Research Foundation and Chief Scientific Officer of the Long COVID Research Consortium, will be the Center’s Scientific Director.
“The Department of Rehabilitation and Human Performance has always prided itself on providing the best possible care of our patients through the emphasis of four core pillars: clinical excellence, research, innovation, and teaching,” says Dr. Herrera. “The CoRE embodies all four of these pillars, enabling us to provide the best possible care with every new clinical tool at our disposal, engaging in novel clinical research and sharing all that we learn with medical students around to world to teach a new generation of medical students to be knowledgeable about the care of complex chronic illness.”
The Cohen Center for Recovery for Complex Chronic Illness will be located at The Mount Sinai Hospital on Manhattan’s Upper East Side. It is projected to open within the coming year and serve roughly 500 new patients annually.
The Cohen Center’s research program will maximize collaboration with the PolyBio Research Foundation's extensive network of scientific teams to analyze samples collected from participants with cutting-edge technologies. These include technologies that can deeply profile the immune response or identify pathogen proteins via sensitive methods not yet available in the clinic. Research will focus on characterizing root-cause drivers of infection-associated chronic disease, including the role of pathogen persistence in tissue.
"Findings from the research program will be immediately communicated to the Cohen Center’s clinical trial team," says Dr. Proal. "That way we are continually growing potential treatment options offered at CoRE based on the latest emerging data."
About the Steven & Alexandra Cohen Foundation
The Steven & Alexandra Cohen Foundation is committed to inspiring philanthropy and community service by creating awareness, offering guidance, and leading by example to show the world what giving can do. The Foundation’s grants support nonprofit organizations based in the United States that either help people in need or solve complex problems. The Foundation also spearheads grassroots campaigns to encourage others to give. As of December 2022, the Foundation has provided over $1 billion of charitable support.
For more information, visit www.steveandalex.org.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Mount Sinai Uses Remote Patient Monitoring to Rapidly Respond to COVID-19
Apr 03, 2020 View All Press Releases